First Time Loading...

Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 0.3558 USD -4.35%
Updated: May 16, 2024

Lyra Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lyra Therapeutics Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Lyra Therapeutics Inc
NASDAQ:LYRA
Operating Income
-$65.5m
CAGR 3-Years
-43%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.3B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$10.6B
CAGR 3-Years
-6%
CAGR 5-Years
11%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.1B
CAGR 3-Years
-12%
CAGR 5-Years
-13%
CAGR 10-Years
-3%
Eli Lilly and Co
NYSE:LLY
Operating Income
$11.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
9%

See Also

What is Lyra Therapeutics Inc's Operating Income?
Operating Income
-65.5m USD

Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Operating Income amounts to -65.5m USD.

What is Lyra Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-55%

Over the last year, the Operating Income growth was -19%. The average annual Operating Income growth rates for Lyra Therapeutics Inc have been -43% over the past three years , -55% over the past five years .